CM Life Sciences II Inc.

CM Life Sciences II Inc., which traded under the ticker SLGC and was sponsored by CM Life Sciences, filed a Form 15-12G with the SEC on January 16, 2024, marking the termination of its registration under Section 12(g) of the Securities Exchange Act. The blank-check company completed its initial public offering in 2020, targeting opportunities in the healthcare and life sciences sector. The filing reflects the conclusion of the entity's public reporting obligations following its de-SPAC business combination with SomaLogic, a proteomics technology company, and the subsequent evolution of that combined entity. For full filing history, sponsor profiles, and deal data on SLGC and thousands of other SPACs, sign up for SpacDesk at spacdesk.com.